Roche licenses Rona Therapeutics’ ALK7 — targeting RNAi obesity drug candidate in deal worth up to $1.16 billion
Roche entered an exclusive worldwide license deal with Rona Therapeutics for an investigational ALK7-targeting RNAi therapy for obesity. Rona will receive up to USD 100 million in upfront and near-term milestone payments. Additional development, regulatory, and commercial milestones could reach USD 1.06 billion, with t